Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

118.92 +0.38 (+0.32%)
Streaming Delayed Price Updated: 11:23 AM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
65 66 Next >
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
From BioNTech SE
Via GlobeNewswire
Is BioNTech Stock a Buy Now?
Or is it too late to get in on the company after its coronavirus-related success? 
Via The Motley Fool
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
From BioNTech SE
Via GlobeNewswire
8 Analysts Have This to Say About BioNTech
Via Benzinga
Price Over Earnings Overview: BioNTech
Via Benzinga
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
From BioNTech SE
Via GlobeNewswire
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
A Look Into BioNTech Inc's Price Over Earnings
Via Benzinga
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Pfizer Reportedly Hikes Paxlovid Price To $1,390 — More Than Double What The Government Paid
The transition to the commercial market is planned for 2024 and could bolster sales. 
Via Investor's Business Daily
7 Stocks That Are Heading for a Train Wreck
There's always a bear market somewhere. Here are seven stocks to sell that investors should definitely unload now. 
Via InvestorPlace
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
From BioNTech SE
Via GlobeNewswire
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories
Benzinga Bitcoin Spiked On False ETF Approval Rumor 
Via Benzinga
Topics ETFs
Benzinga's Top Ratings Upgrades, Downgrades For October 16, 2023
Via Benzinga
Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion
Pfizer cut about $9 billion from its sales expectations for Covid products this year. 
Via Investor's Business Daily
Exposures COVID-19
Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Gainers LQR House Inc. (NASDAQ: LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, securing Von Payne Whiskey's presence on store shelves. 
Via Benzinga
Novavax Faces Setback, European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.  
Via Benzinga
Exposures COVID-19
Pfizer Cuts Annual Revenue Guidance By $9B Amid COVID-19 Vaccine Sales Slump, BioNTech Warns €900M Write-Offs
Friday, Pfizer Inc (NYSE: PFE) slashed its full-year earnings and revenue guidance, citing decreasing demand for its  
Via Benzinga
Exposures COVID-19
BioNTech, Moderna And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Cut Your Losses: Sell These 7 Weak Stocks Now
You can't let weakness in a company or the market damage your portfolio. Avoid disappointing returns by moving on these stocks to sell. 
Via InvestorPlace
Is Novavax Stock a Buy Now?
Is this company just a pandemic stock? 
Via The Motley Fool
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
From BioNTech SE
Via GlobeNewswire
Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
From BioNTech SE
Via GlobeNewswire
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with... 
Via Talk Markets
The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?
Vaccine revenue may have slipped but could still represent billions of dollars for these companies. 
Via The Motley Fool
Exposures COVID-19
7 Innovator Stocks Primed for Exceptional Growth
These featured, inventive companies are not only transforming old sectors but also building bridges toward new ones. 
Via InvestorPlace
Privatized Vaccine Distribution Sparks Confusion, Payment Challenges
As the rollout of the updated COVID-19 vaccine progresses, some individuals have been surprised by requests for upfront payments ranging from $150 to $200.  
Via Benzinga
Exposures COVID-19
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.